Trial Profile
The influence of Rimonabant induced cannabinoid receptor blocking on the mass and function of the left ventricle in patients with abdominal adiposity
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 02 Jun 2013
Price :
$35
*
At a glance
- Drugs Rimonabant (Primary)
- Indications Arrhythmias; Heart failure; Obesity
- Focus Therapeutic Use
- Acronyms ADIPOHEART
- 02 Jun 2013 New trial record